Ironwood taps AstraZeneca as China partner for linaclotide in risk-sharing deal
This article was originally published in Scrip
Executive Summary
Ironwood Pharmaceuticals is on something of a roll with its irritable bowel syndrome (IBS) and constipation drug linaclotide, having received US FDA approval of the first-in-class guanylate cyclase-C agonist in August and then a positive EU approval recommendation last month.